STOCK TITAN
  1. Home
  2. Sec-filings
  3. CPRX
  4. [Form 4] CATALYST PHARMACEUTICALS, INC. Insider Trading Activity

Insider equity awards disclosed by Catalyst Pharmaceuticals (CPRX)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) reported insider equity awards for a director on a Form 4. On November 20, 2025, the reporting person received options to purchase 18,115 shares of common stock at an exercise price of $22.77, and 5,468 restricted stock units (RSUs). On November 21, 2025, 947 RSUs were settled in common stock, increasing the director’s directly held common shares to 2,360.

Following these transactions, the director held 116,555 stock options, 121,076 RSUs, and 2,360 shares of common stock, all directly. The options and RSUs generally vest in three equal annual tranches on specified dates in 2025, 2026, 2027, and 2028, with shares required to be delivered within sixty days of vesting.

Positive

  • None.

Negative

  • None.
Insider Thompson Tamar
Role Director
Type Security Shares Price Value
Exercise Restricted Stock Units 947 $0.00 --
Exercise Common Stock, par value $0.001 per share 947 $0.00 --
Grant/Award Options to purchase common stock 18,115 $0.00 --
Grant/Award Restricted Stock Units 5,468 $0.00 --
Holdings After Transaction: Restricted Stock Units — 121,076 shares (Direct); Common Stock, par value $0.001 per share — 2,360 shares (Direct); Options to purchase common stock — 116,555 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028. Shares of common stock will be delivered to the Reporting Person upon vesting. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thompson Tamar
(Last) (First) (Middle)
355 ALHAMBRA CIRCLE
SUITE 801
(Street)
CORAL GABLES FL 33134
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.001 per share 11/21/2025 M 947 A (1) 2,360 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock $22.77 11/20/2025 A 18,115 (2) 11/20/2032 Common Stock 18,115 $0 116,555 D
Restricted Stock Units (3) 11/20/2025 A 5,468 (2) (3) Common Stock 5,468 $0 122,023 D
Restricted Stock Units (3) 11/21/2025 M 947 (4) (5) Common Stock 947 $0 121,076 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
2. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027 and 1/3rd on November 20, 2028.
3. Shares of common stock will be delivered to the Reporting Person upon vesting.
4. Derivative securities vest in equal tranches, 1/3rd on November 21, 2025, 1/3rd on November 21, 2026, and 1/3rd on November 21, 2027.
5. Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on November 21, 2025.
/s/ Tamar Thompson 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CPRX report on this Form 4?

The Form 4 shows that a director of Catalyst Pharmaceuticals (CPRX) received 18,115 stock options at an exercise price of $22.77, 5,468 RSUs on November 20, 2025, and had 947 RSUs convert into common shares on November 21, 2025.

How many Catalyst Pharmaceuticals (CPRX) options and RSUs does the director hold after the transactions?

After the reported transactions, the director beneficially owned 116,555 stock options and 121,076 RSUs, all reported as held directly, in addition to 2,360 shares of CPRX common stock.

What are the vesting terms for the CPRX options granted on November 20, 2025?

The 18,115 stock options granted on November 20, 2025 vest in three equal tranches: 1/3 on November 20, 2026, 1/3 on November 20, 2027, and 1/3 on November 20, 2028.

How do the CPRX restricted stock units (RSUs) vest and settle for this director?

Certain RSUs vest in three equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027. Each RSU represents a right to receive one CPRX share, and shares must be delivered to the director within sixty days of vesting.

What does each restricted stock unit (RSU) for CPRX represent in this Form 4?

Each restricted stock unit represents a contingent right to receive one share of Catalyst Pharmaceuticals common stock upon vesting, with delivery within sixty days as disclosed.

What was the earliest transaction date reported in this CPRX Form 4 filing?

The earliest transaction date disclosed is November 20, 2025, which is when the director received the grant of 18,115 options and 5,468 RSUs.